The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug Administration (FDA) has approved three new drugs to treat Alzheimer’s since June 2021 ...

Indiana University School of Medicine researchers have identified a new genetic marker that could play a role in the ...

New research shows astrocytes can remove Alzheimer’s-related amyloid-beta via autophagy, offering a promising new direction ...

The money will support the development of Alzheimer's tests specific to tau tangles, the abnormal proteins that form inside ...

Discover the heartbreaking journey of Alzheimer's disease, from forgotten memories to debilitating symptoms. Can psychedelics ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

The 2006 paper had appeared to be an important breakthrough in our understanding of how Alzheimer’s works, providing the precise mechanisms ... Leqembi was approved in 2023. Donanemab now has FDA ...

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

A Princeton-led team of scientists has made an enormous step toward understanding the human brain by building a neuron-by-neuron and synapse-by-synapse roadmap – scientifically speaking, a “connectome ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The hearing focused on a welfare scandal in Mississippi, but the subject of Favre’s health arose because he discussed losing an investment in a company that he believed was making a “breakthrough ...